Aslor Syrup, Tablet
Aslor is a long-acting, tricyclic, non-sedating, selective peripheral histamine H1-receptor antagonist which inhibits the release of pro-inflammatory mediators from human mast cells and basophils.
Allergic Rhinitis: Aslor is used for the relief of the nasal and non-nasal symptoms of allergic rhinitis (Both seasonal and perennial) in patients 2 years of age and older.
Chronic Idiopathic Urticaria: Aslor is also used for the symptomatic relief of pruritus, reduction in the number of hives, and size of hives, in patients with chronic idiopathic urticaria 2 years of age and older.
Aslor is also used to associated treatment for these conditions: Allergic Rhinitis (AR), Asthma, Chronic Idiopathic Urticaria, Common Cold, Nasal Congestion, Perennial Allergic Rhinitis (PAR), Seasonal Allergic Rhinitis, Nasal symptoms, Non-nasal symptoms, Antihistamine
|Other Names||Descarboethoxyloratadine, Desloratadina, Desloratadine|
Desloratadine is bound approximately 82 to 87% to plasma proteins, while its active metabolite, 3-hydroxydesloratadine, is bound approximately 85 to 89%.
|Therapeutic Class||Non-sedating antihistamines|
|Manufacturer||Drug International Ltd|
|Last Updated:||June 23, 2021 at 11:19 am|
Table Of contents
Pediatric drops :
- Child 6 -11 months of age: 2 ml drops once daily
- Child 1 -2 years of age: 2.5 ml drops once daily
- Child 6-11 months of age: 2 ml once daily
- Child 1-5 years of age: 2.5 ml once daily
- Child 6-11 years of age: 5 ml once daily
- Adults & > 12 years of age: 10 ml once daily
- Adults and children 12 years of age and over: 5 mg daily
Aslor is generally well tolerated. However, dry mouth, fatigue, somnolence and myalgia are commonly reported side-effects. Less common side-effects may include dizziness, headache and nausea. Rarely rash, pruritus and urticaria may occur.
Hepatic and renal impairment. Pregnancy and lactation.
Concomitant administration of Erythromycin, Ketoconazole, Azithromycin, Fluoxetine, and Cimetidine with Aslor increased the plasma concentration of Aslor. But there were no clinically relevant changes in the safety profile of Aslor.
- Take with or without food. The absorption is unaffected by food.
Aslor has a mean plasma elimination half-life of approximately 27 hours.
Pregnancy & Breastfeeding use
Pregnancy: There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, Aslor should be used in pregnancy only if clearly needed.
Lactation: Aslor passes into breast milk. Therefore, a decision should be made whether to discontinue nursing or to discontinue Aslor, taking into account the importance of the drug to the mother.
Aslor is contraindicated in patient having hypersensitivity to this medication or to any of its ingredients or Loratadine.
Paediatric Use: The safety and effectiveness of Aslor in pediatric patients under 2 years of age have not been established.
Geriatric Use: In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
In adult patients with liver or renal impairment: A starting dose of one 5 mg tablet every other day is recommended based on pharmacokinetic data.
No clinically relevant adverse events have been reported in case of overdosage. However, in the event of overdosage, symptomatic and supportive treatment is recommended.
Store in a cool and dry place, protected from light.